



Emerald Health Pharmaceuticals to Participate in Neuroscience Panel at the NeuroTech Investing and Partnering Conference

SAN DIEGO, CA, April 30, 2018 – Emerald Health Pharmaceuticals, Inc. (EHP), which is developing medicines based on cannabinoid science, announced today that Dr. Jim DeMesa, CEO, will participate in a panel to discuss how disease modifying treatments may alter the course of movement disorders associated with neurodegenerative diseases at the NeuroTech Investing and Partnering Conference. The conference will take place on Wednesday, May 2nd, 2018 and is being held at the Renaissance Waterfront Hotel in Boston, MA.

Panel: Parkinson's & Other Movement Disorders
10:40 AM ET

About Emerald Health Pharmaceuticals Inc.

EHP is developing synthetic cannabinoid-derived drugs for CNS, autoimmune, and other diseases. The company has two families of patented new chemical entities, derived from cannabidiol (CBD) and cannabigerol (CBG), that have been modified through rational drug design to affect pertinent disease-related targets, including peroxisome proliferator-activated receptor-gamma (PPAR γ), cannabinoid receptor type 2 (CB2), and the hypoxia inducible factor (HIF) pathway, all of which have been validated through decades of published research. Its first drug candidate, EHP-101, is focused on treating multiple sclerosis and scleroderma. Its second, EHP-102, is focused on treating Huntington's disease and Parkinson's disease. The company is completing preclinical development for EHP-101 with the intent to launch a Phase 1 clinical study in 2018.

For more information, visit www.emeraldpharma.life or contact: info@emeraldpharma.life.

Contact

Investor Relations:

Phone: (800) 268-0719

Forward-Looking Statements

To the extent statements contained in this news release are not descriptions of historical facts regarding Emerald Health Pharmaceuticals Inc. they should be considered "forward-looking statements," as described in the Private Securities Litigation Reform Act of 1995, that reflect management's current beliefs and expectations. You can identify forward-looking statements by words such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal,"

“hope,” “hypothesis,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “strategy,” “will,” “would,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in this news release include, but are not limited to, statements regarding: (i) the success and timing of our product development activities and clinical trials; (ii) our ability to develop our product candidates; (iii) our plans to research, discover, evaluate and develop additional potential product, technology and business candidates and opportunities; and (iv) our ability to raise capital. Forward-looking statements are subject to known and unknown factors, risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward looking statements. Undue reliance should not be placed on forward-looking statements. We undertake no obligation to update any forward-looking statements. Emerald Health Pharmaceuticals’ investigational drug products have not been approved or cleared by the FDA. The Offering Circular is available via this [link](#)